Oklo Stock Dips as UBS Adopts Cautious Stance on Nuclear Startup
Shares of Oklo, the small nuclear reactor startup, slid nearly 7% in early trading Wednesday after UBS initiated coverage with a neutral rating. The Swiss bank set a $65 price target—matching current levels—while expressing cautious Optimism about the sector's potential under recent U.S. policy shifts.
Analysts noted Oklo's valuation appears elevated given its lack of revenue, earnings, or free cash flow. The company's commercial viability remains unproven despite the theoretical $75 billion market opportunity in next-gen nuclear technology. UBS declined to recommend buying until concrete commercialization progress emerges.